Camostat clinical trials
Also written FOY-305 and DWJ1248.
How each study uses camostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the camostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2020 (14)
| Year | Studies |
|---|---|
| 2020 | 14 |
| 2021 | 9 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 19
Stanford University (3) · Daewoong Pharmaceutical Co. LTD. (3) · Ono Pharmaceutical Co. Ltd (2) · Yale University (2) · Heinrich-Heine University, Duesseldorf (2) · University of Aarhus (1) · Seoul National University Hospital (1) · Alan Bryce (1)
Often tested with
Tested in the same studies.
Bamlanivimab (1) · Amubarvimab (1) · Romlusevimab (1) · Cilgavimab and tixagevimab drug combination (1) · Interferon beta-1a (1) · Interferon Beta-1a Inhalation Solution SNG001 (1) · Ogalvibart (1) · Crexavibart (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses camostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Effect Camostat for Kidney Protection in Chronic Kidney DiseaseRecruitingPhase 2Odense University HospitalNCT06794593Written as Camostat MesylateHow we know
- The Impact of Camostat Mesilate on COVID-19 InfectionCompletedPhase 1/2University of AarhusNCT04321096Written as Camostat MesilateHow we know
- Camostat Mesylate for Protein-losing Enteropathy After Fontan OperationCompletedPhase 2Seoul National University HospitalNCT05474664Written as Camostat mesylateHow we know
- Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19CompletedPhase 2Alan BryceNCT04470544Written as Camostat MesilateHow we know
- The Potential of Camostat in COVID-19TerminatedPhase 2University Hospital, GhentNCT04625114Written as CamostatHow we know
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as CamostatHow we know
- Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male SubjectsCompletedPhase 1Ono Pharmaceutical Co. LtdNCT04451083Written as FOY-305How we know
- A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)CompletedPhase 3Ono Pharmaceutical Co. LtdNCT04657497Written as FOY-305How we know
- A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)TerminatedPhase 2Cancer Research UKNCT04455815Written as CamostatHow we know
- Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04713176Written as DWJ1248 with RemdesivirHow we know
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master ProtocolCompletedPhase 2Stanford UniversityNCT04662086Written as CamostatHow we know
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-ProtocolTerminatedPhase 2Stanford UniversityNCT04662073Written as CamostatHow we know
- A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2TerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04721535Written as DWJ1248How we know
- Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy VolunteersCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT04782505Written as DWJ1248How we know
- The DAWN Antivirals Trial for Ambulatory COVID-19 PatientsTerminatedPhase 3KU LeuvenNCT04730206Written as CamostatHow we know
- Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 PatientsCompletedPhase 2Stanford UniversityNCT04524663Written as Camostat MesilateHow we know
- The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsWithdrawnPhase 1/2Yale UniversityNCT04435015Written as Camostat MesylateHow we know
- Camostat Mesylate in COVID-19 OutpatientsCompletedPhase 2Yale UniversityNCT04353284Written as Camostat MesilateHow we know
- Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk IndividualsCompletedPhase 2Heinrich-Heine University, DuesseldorfNCT04681430Written as Camostat MesilateHow we know
- CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult PatientsTerminatedPhase 3Assistance Publique - Hôpitaux de ParisNCT04608266Written as Camostat MesylateHow we know
See all 25 studies that test camostat →
As the comparator · 1 — what is tested is compared with camostat
Codes
What other systems call camostat · ClinicalTrials.gg INT003030
- MeSH (NLM) C034532camostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0FD207WKDUCAMOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q5026909camostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73213CamostatOne source FDA
- DrugBank DB13729One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C034532 | camostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0FD207WKDU | CAMOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5026909 | camostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73213 | Camostat | One source FDA |
| DrugBank | DB13729 | — | One source Wikidata |
Also registered as camostat mesylate (UNII 451M50A1EQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.